ELIAZ THERAPEUTICS INC has a total of 31 patent applications. Its first patent ever was published in 2012. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets medical technology, pharmaceuticals and biotechnology are YASUDA SABURO, HUMES H DAVID and PROTERRIS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | Australia | 3 | |
#4 | Canada | 2 | |
#5 | Singapore | 2 | |
#6 | China | 1 | |
#7 | Israel | 1 | |
#8 | Japan | 1 | |
#9 | Republic of Korea | 1 | |
#10 | Mexico | 1 | |
#11 | New Zealand | 1 | |
#12 | WIPO (World Intellectual Property Organization) | 1 | |
#13 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Medical technology | |
#2 | Pharmaceuticals | |
#3 | Biotechnology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Syringes | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Peptides | |
#5 | Analysing materials | |
#6 | Electrotherapy |
# | Name | Total Patents |
---|---|---|
#1 | Eliaz Isaac | 27 |
#2 | Isaac Eliaz | 3 |
Publication | Filing date | Title |
---|---|---|
US2021001032A1 | Galectin-3 plasmapheresis therapy | |
US2017035955A1 | Apheresis based treatment for kidney disease | |
WO2016160644A1 | Patient selective apheresis | |
KR20160102440A | Plasmapheresis device | |
US2014105997A1 | Galectin-3 plasmapheresis therapy | |
EP2941284A1 | Galectin-3 plasmapheresis therapy |